

This is a new page that we are continually improving.

We would love to hear your feedback and suggestions.



Scientific Reports **scientific reports**

[My account](#) ▾

Improving the anti-ageing activity of coenzyme q10 through protransfersome-loaded emulgel

Current status

Congratulations! Your submission has been accepted for publication

We will contact andang-m@ff.unair.ac.id so they can complete the next steps.

Progress so far

Progress so far

1. Submission received - complete
2. Initial technical check - complete
3. Peer review - complete
4. Submission accepted - complete
5. Publishing and rights - in progress

Your submission

Your submission

Title

Improving the anti-ageing activity of coenzyme q10 through protransfersome-loaded emulgel

Type

original-research

Journal

Scientific Reports

Submission ID

a904d626-ce96-4ebd-9a16-6f2ad0d44cb5

Need help?

If you have any questions about this submission, you can [email the Editorial Office](#).

For general enquiries, please look at our [support information](#).

- [Manage cookies / Do not sell my data](#)
- [Help and support](#)
- [Privacy policy](#)
- [Terms and conditions](#)
- [Accessibility statement](#)

© 2023 Springer Nature

Submission history

1. Publishing and rights

Submission status

Date

Submission is in publishing and rights 29 Dec 2021

2. Peer review

Submission status

Date

Submission accepted 29 Dec 2021

Submission under peer review 16 Dec 2021

Submission passed technical check 16 Dec 2021

Revision received 13 Dec 2021

Submission under peer review 14 Sep 2021

3. Technical check

Submission status	Date
Submission passed technical check	14 Sep 2021
Amendment received	14 Sep 2021
Submission is under technical check	01 Sep 2021

4. Submission received

Submission status	Date
Submission received	01 Sep 2021



andang miatmoko <andang-m@ff.unair.ac.id>

Fwd: Your revision is now overdue - Improving the anti-ageing activity of coenzyme q10 through protransfersome-loaded emulgel

7 messages

Bhakti Thakkar <srep@nature.com>
Reply-To: Bhakti Thakkar <srep@nature.com>
To: andang-m@ff.unair.ac.id

Thu, Nov 25, 2021 at 1:34 AM

Dear Prof. Miatmoko,

Re: "Improving the anti-ageing activity of coenzyme q10 through protransfersome-loaded emulgel"

On checking our records, I notice that we were due to receive your revision. Your extension has also expired

To submit your revised manuscript, please use the link: <https://submission.nature.com/submission/61041497-048b-494f-a8ad-3edaa246725c>

Please let us know by replying to this email as soon as possible.

Kind Regards,
Bhakti Thakkar (Ms.)
Editorial Support at [Scientific Reports](#)

On Fri, 5 Nov at 7:31 AM , Andang-m <andang-m@ff.unair.ac.id> wrote:

[External - Use Caution]

Dear Editor,

Regarding the revision of the manuscript, can we get an extension for submission? There are some data that we should collect and summarize to the paper.

We do also need proofreading the manuscript.

Many thanks

On Tue, Oct 19, 2021 at 1:53 PM Scientific Reports <srep@nature.com> wrote:

Ref: Submission ID a904d626-ce96-4ebd-9a16-6f2ad0d44cb5

Dear Dr Miatmoko,

Re: "Improving the anti-ageing activity of coenzyme q10 through protransfersome-loaded emulgel"

We are pleased to let you know that your manuscript has now passed through the review stage and is ready for revision. Many manuscripts require a round of revisions, so this is a normal but important stage of the editorial process.

Editor comments

We regret that the manuscript requires substantial revision for its publication.

Regarding the addition of references:

Authors do not need to cite the articles listed by reviewer #2.

To ensure the Editor and Reviewers will be able to recommend that your revised manuscript is accepted, please pay careful attention to each of the comments that have been pasted underneath this email. This way we can avoid future rounds of clarifications and revisions, moving swiftly to a decision.

Once you have addressed each comment and completed each step listed below, please log in here with the same email you used to submit your manuscript to upload the revised submission and final file:

<https://submission.nature.com/submit-revision/a904d626-ce96-4ebd-9a16-6f2ad0d44cb5>

CHECKLIST FOR SUBMITTING YOUR REVISION

1. Please upload a point-by-point response to the comments, including a description of any additional experiments that were carried out and a detailed rebuttal of any criticisms or requested revisions that you disagreed with. This must be uploaded as a 'Point-by-point response to reviewers' file.

You'll find a handy one-page PDF on how to respond to reviewers' comments here:

https://www.nature.com/documents/Effective_Response_To_Reviewers-1.pdf

2. Please highlight all the amends on your manuscript or indicate them by using tracked changes.

3. Check the format for revised manuscripts in our submission guidelines, making sure you pay particular attention to the figure resolution requirements:

<https://www.nature.com/srep/publish/guidelines>

Finally, if you have been asked to improve the language or presentation of your manuscript and would like the assistance of paid editing services, we can recommend our affiliates, Nature Research Editing Service: <https://authorservices.springernature.com/language-editing> and American Journal Experts: <https://www.aje.com/go/springernature>

Please note that use of an editing service is neither a requirement nor a guarantee of publication. Free assistance is available from our resources page: <https://www.springernature.com/gp/researchers/campaigns/english-language-forauthors>

To support the continuity of the peer review process, we recommend returning your manuscript to us within 21 days. If you think you will need additional time, please let us know and we will aim to respond within 48 hours.

Kind regards,

mitsutoshi setou
Editorial Board Member
Scientific Reports

Reviewer Comments:

Reviewer 1

The manuscript was well-written and the in vivo studies of anti-ageing activity and irritability using UV ray ageing-induced male Balb/c mice provided interesting results. However, the following comments need to be addressed.

- The authors should explain how palisade crystalline liquid was detected under a light microscope. Is polarizing light required for the identification of the crystallinity.
- Improve the Resolution of figure 2.
- The quality of figure 4 was very poor. Please improve its resolution.

- The authors should explain why the color of CoQ10 loaded in emulgel is more intense comparing to the others.
- Protransf-CoQ10 shows similar infrared spectroscopical profiles to Protransfersome blank. What is the concentration of CoQ10 loaded? Would it be possible that the concentration of CoQ10 loaded was insufficient for for the FTIR analysis.
- Differential thermal analysis of Blank protransfersome should be presented and discussed.
- The author mention about the protransfersomal gel mask. What is the difference form the normal protransfersomal gel formulation.
- "The Protransf-CoQ10 was dispersed in an emulgel base consisting of Tween 80 and Span 80 to produce Protransf-CoQ10 gel." The term " emulgel" could lead to the misunderstanding about the composition of the formulation. Normally, gel formulation refers to the three-dimensional polymeric matrix physically or sometimes chemically cross-linked by gelling agents. The author should provide more detail about the polymer used.
- More detail about the in vivo studies of anti-ageing activity and irritability using UV ray ageing-induced male Balb/c mice should be provided in the abstract.

Reviewer 2

Improving the anti-ageing activity of coenzyme q10 through protransfersome-loaded emulgel

Comments to Authors and Editor

The authors presented an interesting "Improving the anti-ageing activity of coenzyme q10 through protransfersome-loaded emulgel". The purpose of the current study is to improve the skin delivery and stability of CoQ10. Although the concept is interesting, yet this study is poorly designed, and the results and discussion have many flaws. Moreover, some basic studies are missing from the manuscript. The detailed comments are given below.

Minor comments:

- 1- Grammatical, typographical and spelling mistakes.
- 2- Before using abbreviation, it should be defined and once defined then should be used throughout the text.
- 3- Space should be given between number and units i.e. line 387 2mL.
- 4- Same spelling should be used for aging. Authors have used ageing and aging.
- 5- Gel preparation method is not clearly defined in methodology section. Please rectify
- 6- The authors have used two term gel and Emulgel, is it same word or there is any difference? The author should use single term.

Major comments:

- 7- In abstract the authors claimed stability studies for 14 weeks while in methodology and results the author has reported 28 days' stability study. On 28 days' study how can one calculate stability of the formulation? Is it according to ICH guidelines?
- 8- The authors has mentioned a particle size of 238 nm for simple CoQ10 gel in table 1, Is it possible for plain drug gel to have size in nm? if yes why the authors formulating nano-formulation? Please Justify?
- 9- The PDI of CoQ10-Ole and Protransf-CoQ10 Gel are same in table 1, while in text the values are different. Also in the same table the authors have reported particle size of 146 nm for CoQ10-Ole, is it possible? Moreover, its difference from the Protransf-CoQ10 Gel seems to be non-significant which needs to be justified.
- 10- In line 160, the authors have mentioned particle size of 201 nm for the formulation, why the particle size is reduced to 134 nm by loading it into gel? Please give valid reasons in the manuscript.
- 11- The authors have discussed that loading the CoQ10 in pro-transfersomes will increase its stability while its zeta potential value is low i.e. -11 ± 5.14 mV. Please justify
- 12- The authors have not provided any figure of DLS results. Please add
- 13- Carbopol is water soluble, why the authors used two surfactants with it i.e. lipophilic and hydrophilic. Please justify in the manuscript
- 14- The authors have claimed an entrapment of 45% for the final transfersomal formulation. However, transfersomes have been reported with capability of 97% drug entrapment and

excellent skin deposition. What are the main reasons of low drug entrapment in this system? How the authors justify the superiority of their developed system over the already existed systems. Please discuss in the manuscript.

15- In figure 5, on day 0 the authors have shown difference in the size and pH, is it possible?

16- Table 2 is confusing, why the authors added only CoQ10 in protransferosomes and lipid and surfactant in simple CoQ10 dispersion.

17- In discussion section, the authors claimed the conversion of pro-transferosomes into transferosomes which is in contradiction with the text in introduction in which the author mentioned in situ formation of transferosomes. If the conversion occurs during loading into gel what is the purpose of protransferosomes formulation. Please respond.

18- In figure 6 the collagen density is higher in CoQ10-Ole treated group as compared to Protransf-CoQ10 group while these results are in contradiction with figure 7 results in which authors have shown higher number of fibroblast in Protransf-CoQ10 group. As fibroblast are collagen forming cells if their number is high in Protransf-CoQ10 treated group then collagen density must also be higher. Please respond in the discussion section.

19- Same can be seen in case of normal and CoQ10-Ole group, where difference in collagen density is significant while the number of fibroblast are almost same. Please respond

20- The authors have used the word Protransf-CoQ10 mask in the text repeatedly, but no such information is provided in the results or discussion. How Carbopol gel will form a mask? Please explain.

21- The authors didn't conducted any release study for the prepared formulation, which is an important aspect of drug delivery. Please respond.

22- Authors have not performed any permeation or deposition study please respond why?

23- The author have claimed that due to higher lipid concentration protransferosomes are preferred over transefersomes. However, most of the transfersomes have been reported with the same (85:15) ratio, which same with that used for transferosomesas reported by authors for protransferosomes. Please Justify

24- It is very surprising that the authors have not reported any characterization of the gel, being the final product gel characterization is of prime importance. Please respond.

25- The characteristic of 3 prepared gel i.e. color given in the text are in contradiction with the explanation in the text.

26- Melting point of CoQ10 is 48-52 C°, why the author has selected range of 30-300 C° in DSC study. Also please add Temperature range in Figure 4.

27- It is highly recommended to check the drug content, particle size and zeta potential of the formulation in stability study for at least 3-4 months as per the ICH guidelines.

28- Which animal models were used for Skin irritation and other in vivo studies? Please report in the manuscript.

29- References are missing in methodology section i.e. antiaging study. The authors are advised to add the following references.

<https://doi.org/10.1080/03639045.2021.1890768>

<https://doi.org/10.1155/2021/9968602>

[10.2217/nnm-2019-0320](https://doi.org/10.2217/nnm-2019-0320)

<https://doi.org/10.1016/j.jsps.2011.08.001>

****Our flexible approach during the COVID-19 pandemic****

If you need more time at any stage of the peer-review process, please do let us know. While our systems will continue to remind you of the original timelines, we aim to be as flexible as possible during the current pandemic.

--
Salam,

[Andang Miatmoko, PhD., Apt.](#)
Department of Pharmaceutical Sciences
Faculty of Pharmacy, Airlangga University
Nanizar Zaman Joenoes Building
Campus C Airlangga University, Mulyorejo, 60115
Surabaya

Andang MIATMOKO <andang-m@ff.unair.ac.id>
To: Bhakti Thakkar <srep@nature.com>

Wed, Nov 24, 2021 at 10:43 PM

Dear Dr. Thakkar,

Many thanks for your email, I am still struggling to collect the data since our experiments have been performed in other laboratories, however I have no courage to ask for a re-extension for submission. Could you please give us some advice? many thanks

[Quoted text hidden]

Bhakti Thakkar <srep@nature.com>
Reply-To: Bhakti Thakkar <srep@nature.com>
To: andang-m@ff.unair.ac.id

Thu, Nov 25, 2021 at 9:39 PM

Dear Prof. Miatmoko,

Thank You for getting back to us.

Please do not hesitate if you need any help. We are there to assist you.

We prefer our authors to be completely happy with what they submit and what we can do is grant another grand extension, we have no issue with it.

I look forward to from hearing you.

[Quoted text hidden]

Andang MIATMOKO <andang-m@ff.unair.ac.id>
To: Bhakti Thakkar <srep@nature.com>

Fri, Nov 26, 2021 at 7:19 PM

Dear DR Thakkar,

Many thanks for your email. I really appreciate it and thank you very much for your kind help.

Please allow me to finish the revision within 2 weeks, it really helps me a lot

I will send it once the revision is done.

Thank you

[Quoted text hidden]

Bhakti Thakkar <srep@nature.com>
Reply-To: Bhakti Thakkar <srep@nature.com>
To: andang-m@ff.unair.ac.id

Mon, Nov 29, 2021 at 4:37 PM

Hello Prof. Miatmoko,

Thank You for your email.

We have extended the date to 13 December 2021.

Kind Regards,

Bhakti Thakkar (Ms.)

Editorial Support at [Scientific Reports](#)

[Quoted text hidden]

, Andang-m <andang-m@ff.unair.ac.id> wrote:

[Quoted text hidden]

[Quoted text hidden]

[Quoted text hidden]

[Quoted text hidden]

, Andang-m <andang-m@ff.unair.ac.id> wrote:

[Quoted text hidden]

[Quoted text hidden]

--

Salam,

Andang Miatmoko, PhD., Apt.

Department of Pharmaceutical Sciences
Faculty of Pharmacy, Airlangga University
Nanizar Zaman Joenoes Building
Campus C Airlangga University, Mulyorejo, 60115
Surabaya

--

Salam,

Andang Miatmoko, PhD., Apt.

Department of Pharmaceutical Sciences
Faculty of Pharmacy, Airlangga University
Nanizar Zaman Joenoes Building
Campus C Airlangga University, Mulyorejo, 60115
Surabaya

Andang MIATMOKO <andang-m@ff.unair.ac.id>
To: Bhakti Thakkar <srep@nature.com>

Wed, Dec 15, 2021 at 1:31 PM

Dear Dr. Thakkar,
I am sending the certificate of proofread. please see the attached file.
many thanks

[Quoted text hidden]



Certificate of Proofreading Andang Miatmoko et al. 14-12-21.jpg
196K

Bhakti Thakkar <srep@nature.com>
Reply-To: Bhakti Thakkar <srep@nature.com>
To: andang-m@ff.unair.ac.id

Wed, Dec 15, 2021 at 1:37 PM

Dear Prof. Miatmoko,

Thank you for sharing the certificate.

We have received the submission in good order. It will undergo std. quality check and if nothing required we will inform the handling editor.

Kind Regards,
Bhakti Thakkar (Ms.)
Editorial Support at Scientific Reports

On Wed, 15 Dec at 6:31 AM , Andang-m <andang-m@ff.unair.ac.id> wrote:

[External - Use Caution]

Dear Dr. Thakkar,

[Quoted text hidden]

[Quoted text hidden]

[Quoted text hidden]

[Quoted text hidden]

, Andang-m <andang-m@ff.unair.ac.id> wrote:

[Quoted text hidden]

[Quoted text hidden]

--

Salam,

[Andang Miatmoko, PhD., Apt.](#)

Department of Pharmaceutical Sciences
Faculty of Pharmacy, Airlangga University
Nanizar Zaman Joenoes Building
Campus C Airlangga University, Mulyorejo, 60115
Surabaya

--

Salam,

[Andang Miatmoko, PhD., Apt.](#)

Department of Pharmaceutical Sciences
Faculty of Pharmacy, Airlangga University
Nanizar Zaman Joenoes Building
Campus C Airlangga University, Mulyorejo, 60115
Surabaya



andang miatmoko <andang-m@ff.unair.ac.id>

Scientific Reports: Decision on your manuscript

1 message

Scientific Reports <srep@nature.com>
To: andang-m@ff.unair.ac.id

Wed, Dec 29, 2021 at 9:06 PM

Ref: Submission ID a904d626-ce96-4ebd-9a16-6f2ad0d44cb5

Dear Dr Miatmoko,

Re: "Improving the anti-ageing activity of coenzyme q10 through protransfersome-loaded emulgel"

We're delighted to let you know your manuscript has now been accepted for publication in Scientific Reports.

Editor comments

I am happy to accept the revised manuscript.

Licence to Publish

As the corresponding author of an accepted manuscript, you must complete an Open Access Licence to publish on behalf of all authors. To do this, you'll need a [nature.com](https://www.nature.com) account based on your andang-m@ff.unair.ac.id email. If you already have such an account, please complete the statement here:

<https://editorial.nature.com/submissions/a904d626-ce96-4ebd-9a16-6f2ad0d44cb5/publication-agreement/5719ec31-1d54-4dac-97b4-3f1612f293d3>

If you don't yet have a [nature.com](https://www.nature.com) account linked to andang-m@ff.unair.ac.id, you can create one here:

https://idp.nature.com/unified/register/stoa?redirect_uri=https%3A%2F%2Feditorial.nature.com%2Fsubmissions%2Fa904d626-ce96-4ebd-9a16-6f2ad0d44cb5%2Fpublication-agreement%2F5719ec31-1d54-4dac-97b4-3f1612f293d3

Article Processing Charge

You will shortly receive an email asking you to confirm your institutional affiliation and arrange payment of your article-processing charge (APC), if applicable. To find out more about APCs, visit our support portal: <https://support.springernature.com/en/support/solutions/6000138386>

Checking the proofs

Prior to publication, our production team will also check the format of your manuscript to ensure that it conforms to the standards of the journal. They will be in touch shortly to request any necessary changes, or to confirm that none are needed.

Once we've prepared your paper for publication, you will receive a proof. At this stage, please check that the author list and affiliations are correct. For the main text, only errors that have been introduced during the production process, or those that directly compromise the scientific integrity of the paper, may be corrected.

Please make sure that only one author communicates with us and that only one set of corrections is returned. As the corresponding (or nominated) author, you are responsible for the accuracy of all content, including spelling of names and current affiliations.

To ensure prompt publication, your proofs should be returned within two working days.

Publication policies

Acceptance of your manuscript is conditional on all authors agreeing to our publication policies at: <https://www.nature.com/srep/journal-policies/editorial-policies>.

Your article will be open for online commenting on the Scientific Reports website. Please use the report facility if you see any inappropriate comments, and of course, you can contribute to discussions yourself. If you wish to track comments on your article, please register by visiting the 'Comments' section in the full text (HTML) version of your

paper.

A form to order reprints of your article is available at <https://www.nature.com/reprints/author-reprints.html>. To obtain the special author reprint rate, orders must be made within a month of the publication date. After that, reprints are charged at the normal (commercial) rate.

Once again, thank you for choosing Scientific Reports, and we look forward to publishing your article.

Kind regards,

mitsutoshi setou
Editorial Board Member
Scientific Reports

P.S. If appropriate, you may also consider uploading any protocols used in this manuscript to the protocol exchange, part of our online web resource, <https://protocolexchange.researchsquare.com>. By participating, you are enabling researchers to reproduce or adapt your methodology. The protocol exchange is fully searchable, providing your protocols and paper with increased utility and visibility. Protocols can also be easily updated via versioning. Please submit your protocol to <https://protocolexchange.researchsquare.com/submission>. You may need to create a new Research Square account. Please provide details of this article in the associated publications section. You'll find more information at: <https://protocolexchange.researchsquare.com>

** Visit the Springer Nature Editorial and Publishing website at www.springernature.com/editorial-and-publishing-jobs for more information about our career opportunities. If you have any questions, please email Editorial.Publishing.Jobs@springernature.com. **

1 **Improving the anti-ageing activity of coenzyme q10 through protransfersome-loaded**
2 **emulgel**

3
4
5 **Qurrota Ayunin^{1,2}, Andang Miatmoko^{3,*}, Widji Soeratri³, Tristiana Erawati³, Joni**
6 **Susanto⁴, Djoko Legowo⁵**

7
8 ¹ Master Program of Pharmaceutical Sciences, Department of Pharmaceutical Sciences,
9 Faculty of Pharmacy, Universitas Airlangga Nanizar Zaman Joenoes Building, Campus C
10 Mulyorejo, Surabaya, 60115, Indonesia

11 ² Study Program of Pharmacy, Faculty of Pharmacy, Hospital Administration, Public Health,
12 and Radiology, Institut Ilmu Kesehatan STRADA, Jl. Manila 37, Kediri, 64133, Indonesia

13 ³ Department of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga,
14 Nanizar Zaman Joenoes Building, Campus C Mulyorejo, Surabaya, 60115, Indonesia

15 ⁴ Department of Anatomy and Histology, Faculty of Medicine, Universitas Airlangga, Jl.
16 Mayjen. Prof. Dr. Moestopo No. 47, Campus A Mulyorejo, Surabaya, 60132, Indonesia

17 ⁵ Department of Veterinary Pathology, Faculty of Veterinary Medicine, Universitas
18 Airlangga, Jl. Mayjen. Prof. Dr. Moestopo No. 47, Campus C Mulyorejo, Surabaya, 60115,
19 Indonesia

20
21 Running Title: Improving the anti-ageing activity of coenzyme Q10 through protransfersome

22
23 * To whom correspondence should be addressed:

24 E-mail address: andang-m@ff.unair.ac.id

25 Tel/fax: +62-31-5933-150/+62-31-5935-249

26 **Abstract**

27 **Coenzyme Q10 (CoQ10)** is a naturally produced organic molecule which acts as an
28 antioxidant agent, including in skin anti-ageing, and plays a major role in the social
29 determinants of health. However, its level in the body will decrease during ageing. Therefore,
30 an external supplement is required to repair damaged skin, especially the skin dermis layer.
31 This study aims to evaluate the use of a protransfersomal **emulgel** to improve the skin
32 delivery and stability of CoQ10 which demonstrates low water solubility, poor permeability
33 and instability. CoQ10 was initially dissolved in oleic acid at a weight ratio of 1:56.
34 Protransfersome was then loaded with CoQ10 (Protransf-CoQ10) and prepared using a
35 composition of L- α -Phosphatidylcholine and Tween 80 at a molar ratio of 85:15. The
36 Protransf-CoQ10 was dispersed in an emulgel base consisting of Tween 80 and Span 80 to
37 produce Protransf-CoQ10 emulgel. **The *in vivo* studies of anti-ageing activity and irritability**
38 **were further evaluated by applying daily 200 mg of emulgels twice a day to a 4 cm² section**
39 **on the back of a UV-ray aging-induced male Balb/c mouse 20 minutes before irradiation.** The
40 results showed that Protransf-CoQ10 could transform into transfersomal vesicles with
41 particle sizes of approximately 201.5 ± 6.1 nm and a zeta potential of -11.26 ± 5.14 mV. **The**
42 **dispersion of Protransf-CoQ10 into emulgel base resulted in stable Protransf-CoQ10 Emulgel**
43 **during 28 days of observation at low temperatures.** Moreover, the *in vivo* study revealed that
44 Protransf-CoQ10 Emulgel successfully increases the collagen density and number of
45 fibroblast cells in UV radiation skin-aged induced-mice which reflects its potential for
46 repairing the skin ageing process. In addition, the 24-hour topical application of Protransf-
47 CoQ10 Emulgel showed that no erythema or skin rash was observed during the study. In
48 conclusion, loading CoQ10 into protransfersomal Emulgel successfully enhanced the stability
49 and anti-ageing efficacy enabling its potential use as anti-ageing cosmetics.

50 Keywords: social determinants of health, coenzyme Q10, protransfersome, emulgel, anti-
51 ageing cosmetics

52

53 **Introduction**

54 Premature skin ageing occurs because the skin, as the outermost organ, is always directly
55 exposed to oxidants in the environment and is frequently a determining factor in social life.

56 In addition, with increasing age, the activity of mitochondria in the body as a producer of
57 energy in regenerating cells and tissues decreases¹. Both these internal and external factors
58 cause impaired tissue function and structural changes² culminating in skin ageing
59 characterized by thinning of the epidermis and skin dermis and, ultimately, resulting in
60 wrinkles, fine facial lines, and loss of elasticity^{3,4}. Skin elasticity is largely dependent upon
61 young collagen fibers and fibroblasts, collagen-producing cells in the dermis layer, whose
62 numbers decrease during the ageing process⁵.

63 Anti-ageing cosmetics have been widely used to promote skin regeneration, especially
64 of the upper skin layers which protect the skin against dehydration, penetration by various
65 microorganisms, allergens, irritants, reactive oxygen species (ROS) and radiation, thereby
66 maintaining healthy skin⁶. Coenzyme Q10 (CoQ10) is one of the natural compounds often
67 employed as an antioxidant, which plays a key role in stabilizing plasma and other
68 intracellular membranes that protect against membrane phospholipid peroxidation⁷. CoQ10
69 acts by maintaining skin quality against free radicals³ which have been known to activate the
70 mitogen-activated protein kinase (MAPK) pathway that produces matrix metalloproteinases
71 (MMPs) such as collagenase, thus damaging collagen fibers⁸⁻¹⁰. During ageing, the levels of
72 CoQ10 in organs, including the skin, also decrease with the result that it is necessary to
73 supply CoQ10 to achieve normal levels of between 0.50 and 1.65 µg/mL within the body.

74 Topical administration of CoQ10 has been shown to be effective in reducing wrinkles in skin
75 that has been exposed to UV rays³.

76 CoQ10 demonstrates low solubility in water (0.193 µg/mL) with a large molecular
77 weight of 863.36 g/mol and high lipophilicity with a log P value of 21. This limits its
78 penetration of the skin and explains its tendency to be deposited in the stratum corneum¹¹.
79 Moreover, CoQ10 decomposes when exposed to light¹². Loading CoQ10 into
80 protransfersome, a vesicular carrier would probably constitute an effective strategy to
81 enhance its biological activity within the skin in addition to increasing its stability.

82 Protransfersome, one of the provesicular nanocarriers that provides superior skin
83 penetration and high stability, is widely used in transdermal delivery¹³. It possesses a
84 flattened liquid crystal structure which is converted into an ultraflexible vesicle known as
85 transfersome through the absorption of water from the skin during *in situ* hydration¹⁴⁻¹⁶.
86 Transfersome is known to be an ultradeformable vesicle which is highly flexible and
87 deformable, rendering it capable of passing through three skin penetration pathways¹⁷.
88 Transfersome can rapidly penetrate the stratum corneum and enter the deeper skin layers via
89 the intercellular lipid of the stratum corneum. It can fuse with the cell membrane, enabling it
90 to enter the transcellular pathway, and is able to penetrate intact through the hair follicle
91 pathway to penetrate the deeper layers of the skin¹⁸⁻²⁰. Protransfersome is composed of
92 amphiphatic lipid components such as phosphatidylcholine which, significantly, form double-
93 layer membrane of vesicles, and surfactant as an edge activator that increases the vesicle
94 flexibility or deformability²¹. In general, protransfersome contains a larger number of
95 phospholipids than that present in transfersomes. During the manufacturing process, the
96 protransfersome does not undergo an extrusion process to produce unilamellar vesicles as
97 observed in the transfersome. This is because the protransfersome is a provesicular carrier
98 system which will be converted into transfersome after it comes into contact with water in

99 situ²². Therefore, under a light microscope, the protransfersome can be seen to possess a
100 palisade crystalline liquid form, whereas transfersomes are vesicular when in liquid media²³.

101 The use of ultradeformable vesicles has successfully improved the skin penetration of
102 drugs and efficacy of anti-ageing properties of certain antioxidant molecules such as
103 tocopherol which, when prepared in transfersome, possess good characteristics with a particle
104 size <100 nm and entrapment efficiency of up to 90%. Moreover, it is well distributed within
105 the skin layer and *in vitro* tests have proved it biocompatible with keratinocytes and
106 fibroblasts, indicating its protective effect against oxidative damage and the potential for
107 wound healing²⁴. Previous reports have evaluated the use of nanocarriers for CoQ10 delivery
108 such as a self-emulsifying drug delivery system (SEDDS)²⁵, ethosomes²⁶, transethosomes²⁷,
109 and microemulsion²⁸. The use of transethosomes successfully encapsulated CoQ10 up to 97%
110 in vesicles and produced >95% drug deposition in different skin layers resulting in high
111 efficacy for androgenic alopecia²⁷. The low water solubility of CoQ10 frequently limits drug
112 encapsulation efficiency in nanocarriers, thus the use of large amounts of lipid phase or
113 ethanol may improve its loading.

114 In this study, a protransfersome containing CoQ10 will be prepared for anti-ageing
115 emulgel. The high level of phospholipids contained in protransfersome is intended to improve
116 drug loading. The use of protransfersome in the anti-ageing activity and irritation level of
117 Protransf-CoQ10 emulgel was evaluated *in vivo* using UV-induced aged mice models. This
118 study could represent an attempt to improve CoQ10 anti-ageing activity with the result that is
119 effective, safe and non-irritating.

120

121


122 **Results**

123 This study aims to evaluate the potential use of protransfersome for topical delivery of
124 CoQ10 as an anti-ageing agent. This study provides a scientific approach to successfully
125 delivering low water solubility and poor permeable lipophilic substances and nanovesicular
126 carriers specifically designed for anti-ageing cosmetics. The CoQ10 was loaded into
127 protransfersomal emulgel composed of oleic acid containing soluble CoQ10, phospholipids
128 as bilayer-forming lipids, and Tween 80 which acts as the edge activator of bilayer membrane
129 after the protransfersome has been hydrated with skin water *in situ*, before being loaded into
130 an emulgel base. There were improvements in stability and potential efficacy to inhibit
131 premature ageing of the skin in UV-radiation skin aged-induced mice models as
132 demonstrated in this study.

133

134 **Physical Characteristics and Stability of Protransfersome-Loaded CoQ10 Emulgel**

135 After dissolving the CoQ10 in oleic acid and encapsulated it into protransfersomes
136 composed of phospholipids and Tween 80, the protransfersome-loaded CoQ10 (Protransf-
137 CoQ10) forms a bright orange, viscous, oily liquid, with a distinctive phospholipid smell, and
138 viscous consistency. After hydration with saline, lamellar vesicular structures rapidly formed
139 and were ultimately transformed into transfersome vesicles, as shown in Figure 1.




140

141 **Figure 1.** Lamellar structure of liquid crystals of the CoQ10 protransfersome emulgel after
 142 adding one drop of saline under an optical microscopy observation at 400x magnification
 143 (Scale bar:100 μm).

144

145 The dispersion of Protransf-CoQ10 into the emulgel base (Figure 2A-B) at a weight ratio of
 146 2:1 produced Protransf-CoQ10 Emulgel whose color changes to brownish orange with a
 147 reduction in its pungent smell as shown in Figure 2C. CoQ10 dissolved in oleic acid (CoQ10-
 148 Ole) was in the form of a bright orange odorless emulgel (Figure 2D) whose character is
 149 identical to that of CoQ10 Emulgel except that it is more transparent due to no oleic acid
 150 being present in the formula (Figure 2E). The darkening color of Protransf-CoQ10 emulgel
 151 probably due to large amount of L- α -Phosphatidylcholine content of which is dark yellow in
 152 color²⁹ and easily oxidized when it is exposed to air in for lengthy periods^{30,31}.

153



154
 155 **Figure 2.** Visual appearance of protransfersomal CoQ10 (Protransf-CoQ10) (A), emulgel
 156 base (B), protransfesomal CoQ10 (Protransf-CoQ10) Emulgel (C), CoQ10 dissolved in oleic
 157 acid (CoQ10-Ole) Emulgel (D), and CoQ10 loaded in emulgel (CoQ10 Emulgel) (E). The
 158 Intensity distribution of particle of protransfesomal CoQ10 (Protransf-CoQ10) Emulgel (F),
 159 CoQ10 dissolved in oleic acid (CoQ10-Ole) Emulgel (G), and CoQ10 loaded in emulgel
 160 (CoQ10 Emulgel) (H).

161
 162 The particle size and polydispersity index value were further evaluated since they
 163 determine the ability of the vesicles to penetrate the deeper layers of the skin. The smaller the
 164 particle size of the vesicles, the easier the vesicles are to penetrate. In addition, the smaller
 165 the polydispersity index value, the more homogeneous the particle size of the vesicles¹⁶, thus
 166 ensuring that a larger number of vesicles penetrate the skin. From the results, it is evident that
 167 the entrapment efficiency value of the CoQ10 in Protransf-CoQ10 is comparatively high at

168 45.64 ± 7.52% with particle size of 201.5 ± 6.1 nm (by manual shaking method),
 169 polydispersity index value of 0.229 ± 0.047, and ζ-potential of -11.26 ± 5.14 mV, as
 170 presented in Table 1. The manual shaking method of five minutes' duration was reflective of
 171 the real situation in which protransfersomes change into transfersomes. The Protransf-CoQ10
 172 Emulgel had the smallest particle size compared to both CoQ10-Ole Emulgel and CoQ10
 173 Emulgel, which were 134.3 ± 4.8 nm < 146.9 ± 1.6 nm < 238.8 ± 3.1 nm, respectively, with
 174 intensity distribution of particle presented in Figure 2F-H. The polydispersity index values
 175 for Protransf-CoQ10 Emulgel, CoQ10-Ole Emulgel, and CoQ10 Emulgel were 0.291 ± 0.020
 176 < 0.298 ± 0.019 < 0.384 ± 0.010.


177

178 **Table 1.** Particle Size and polydispersity index of CoQ10 loaded in emulgel (CoQ10
 179 Emulgel), CoQ10 dissolved in oleic acid (CoQ10-Ole) Emulgel, and protransfesomal CoQ10
 180 (Protransf-CoQ10) Emulgel. Each value represents the mean ± SD (n = 3).

Formula	Particle size (nm)	Polydispersity index (PDI)
CoQ10 Emulgel	±	± 0.010
CoQ10-Ole Emulgel	±	±
Protransf-CoQ10 Emulgel	134.3 ± 4.8	± 0.020

181

182 In order to evaluate any interaction between CoQ10 and protransfersomal matrix, a
 183 Fourier Transform Infra Red (FTIR) analysis was further observed. As presented in Figure 3,
 184 there were no new absorption bands of functional groups or peak shifts observed for
 185 Protransf-CoQ10, which shows similar infrared spectroscopical profiles to Protransfersome
 186 blank, while no specific peaks of CoQ10 appear. This result indicates that CoQ10
 187 successfully encapsulated protransfersome and no chemical interaction between the mixtures
 188 occurred³²⁻³⁴.




189

190 **Figure 3.** Fourier-transform infrared spectra of Coenzyme Q10 (CoQ10), Blank
191 protransfersome, and protransfersome loaded CoQ10 (Protransf-CoQ10).

192

193 Moreover, according to the result of differential thermal analysis, the CoQ10
194 encapsulation into protransfersome produced changes in the structure of cristallinity. CoQ10
195 and L- α -Phosphatidylcholine showed sharp endothermic peaks at 53.3 and 112.3°C,
196 respectively; however, protransfersomal CoQ10 showed weak endothermic peak at 143.9°C
197 indicating that less ordered crystalline structures were observed as presented in Figure 4.




198

199 **Figure 4.** Differential thermal analysis of Coenzyme Q10 (CoQ10), L- α -Phosphatidylcholine
 200 as phospholipid component of protransfersome, and protransfersome loaded CoQ10
 201 (Protransf-CoQ10).

202

203 A physical stability test was subsequently carried out to determine the physical
 204 resistance of the system when stored at different temperatures, namely; room temperature and
 205 a lower temperature for 28 days. During the study, the parameters of particle size,
 206 polydispersity index, and pH were observed. As seen from Figure 5, the results showed that
 207 after a 28-day storage period, there were no significant differences in particle size or
 208 polydispersity index ($P < 0.05$). On the other hand, a significant difference was observed in
 209 the pH during the same period, although the pH value remained within the pH range of the
 210 skin. No significant difference existed in the particle size or particle size distribution of the
 211 preparation after 28 days of storage.



212


213 **Figure 5.** Evaluation of particle size, polydispersity index, and pH stability of
 214 protransfersomal CoQ10 loaded in emulgel (Protransf-CoQ10 Emulgel) during 28 days
 215 stored at room ($25 \pm 2^\circ\text{C}$) and cool ($4 \pm 2^\circ\text{C}$) temperatures.

216

217 ***In vivo* Anti-ageing Activity of Protransfersome-Loaded CoQ10 Emulgel**

218 To evaluate the ability of protransfersomes to topically deliver CoQ10 and produce an
 219 effective anti-ageing activity, the Protransf-CoQ10 Emulgel was topically applied for 14 days
 220 to the back skin of UV-rays-induced subjects who were subsequently observed for skin
 221 histopathology. The control group subjects which received UV rays had the lowest collagen
 222 density of $52.30 \pm 7.87\%$, indicating that UV rays damage the collagen in the skin dermis.
 223 The administration of both Protransf-CoQ10 Emulgel and CoQ10-Ole Emulgel significantly
 224 improved the collagen density of UV-ray radiated subjects' skin as indicated in Figure 6.
 225 However, there was no significant difference between these groups. The use of


226 protransfersomes successfully delivered CoQ10 providing protection against skin damage
227 and repaired that resulting from exposure to UV rays.



228
229 **Figure 6.** The collagen density of dermis layer of subject's back skin without and with UV-
230 induced photoageing after topically applied with saline (Normal skin and UV-induced skin),
231 CoQ10-loaded Emulgel, CoQ10 dissolved in oleic acid (CoQ10-Ole) Emulgel, and
232 protransfesomal CoQ10 (Protransf-CoQ10) Emulgel once every two days for two weeks.
233 * $P < 0.05$ compared to UV-induced skin, # $P < 0.05$ compared to Normal Skin.

234
235 The anti-ageing activity test result was further analyzed by observing the number of
236 fibroblast cells capable of producing collagen. Therefore, the higher the number of
237 fibroblasts, the more collagen was formed. In this study, the assessed fibroblasts were young
238 and light purple in appearance. The results showed that the CoQ10 Emulgel had a
239 significantly different number of fibroblasts compared to the control group, with pro-CoQ10

240 Emulgel producing the highest number of fibroblasts, which was 31.50 ± 9.48 cells per field
241 view, as indicated in Figure 7. This shows that protransfersomes delivering CoQ10
242 successfully increase the number of fibroblasts.




243
244 **Figure 7.** The number of fibroblasts of mice back skin without and with UV-induced
245 photoaging after topically applied with saline (Normal skin and UV-induced skin), CoQ10-
246 loaded Emulgel, CoQ10 dissolved in oleic acid (CoQ10-Ole) Emulgel, and protransfesomal
247 CoQ10 (Protransf-CoQ10) Emulgel once every two days for two weeks. * $P < 0.05$ compared
248 to UV-induced skin, # $P < 0.05$ compared to Normal Skin, \$ $P < 0.05$ compared to CoQ10-Ole
249 treated skin.

250

251 *In vivo* Skin Irritation Test

252 The safe use of Protransfersome-loaded emulgels in this study was also evaluated by
253 conducting an in vivo irritation test. Epidermis liquefaction, subepidermis edema, collagen


254 fiber swelling, inflammatory cells infiltration, dan appendages degeneration were observed
255 for determining irritation in model's skin. As presented in Figure 8, there are differences in
256 skin histopathology between normal and UV-induced skin. For further evaluation of severity
257 level of skin irritation, scoring was then determined for each group.



258
259 **Figure 8.** The histopathology of mice back skin stained with Hematoxylin-Eosin without and
260 with UV-induced photoageing at 24 hours after topically applied with saline (Normal skin
261 and UV-induced skin), CoQ10-loaded Emulgel, CoQ10 dissolved in oleic acid (CoQ10-Ole)
262 Emulgel, and protransfesomal CoQ10 (Protransf-CoQ10) Emulgel.

263
264 The results of the histopathological scoring of the models' back skin after 24 hours of
265 application showed that CoQ10 Emulgel had an irritation score of 0.52, while CoQ10-Ole
266 Emulgel had one of 1.36, and Protransf-CoQ10 Emulgel one of 0.92 as presented in Figure 9.
267 This result shows that the Protransf-CoQ10 Emulgel does not irritate the skin, while the
268 CoQ10-Ole Emulgel induced mild irritation due to the nature of oleic acid. According to the

269 Kruskal Wallis statistical test results, there was no significant difference between these
270 emulgel preparations.



271

272 **Figure 9.** The scoring results of histopathology of mice back skin s without and with UV-
273 induced photoageing at 24 hours after topically applied with saline (Normal skin and UV-
274 induced skin), CoQ10-loaded Emulgel, CoQ10 dissolved in oleic acid (CoQ10-Ole) Emulgel,
275 and protransfesomal CoQ10 (Protransf-CoQ10) Emulgel.

276

277

278

279 Discussion

280 In this study, the Protransfersomes and Protransfersomal emulgel preparations for CoQ10
281 delivery as the active cosmetic ingredient have the potential to inhibit premature ageing of
282 the skin. The main purpose of protransfersome formulation is to significantly encapsulate
283 CoQ10 in order to modify the physicochemical characteristics of CoQ10, rendering it more
284 water dispersible and able to penetrate the skin since high lipophilic CoQ10 demonstrates low
285 water solubility and poor skin penetration. However, the high content of oleic acid, which
286 accounted for approximately 37% of the final weight of protransfersomal emulgel, would
287 render it unacceptable for daily use as a skin cosmetic. Therefore, it was added to emulgel to
288 increase its appropriateness for use. As far as the functional aspects of vesicles are concerned,
289 the formation of transfersome due to hydration of protransfersome by water content in the
290 emulgel base produces ultra-deformable vesicles which allow them to easily penetrate the
291 skin. In addition, previous reports showed that the presence of a gelling agent would act as a
292 steric hindrance which would be adsorbed onto the vesicle surface preventing fusion or
293 aggregation, thus increasing physical stability during storage^{35,36}. The addition of lipid
294 vesicles to gel is beneficial for increasing vesicle stability, prolonging drug release,
295 improving dermal permeability, and enhancing drug deposition in the skin³⁷.

296 Protransfersomes have been developed as the nanometer-sized carrier form of
297 transfersome provesicles and have a higher phospholipid content compared to transfersomes.
298 This enables the protransfersome system to demonstrate greater entrapment efficiency due to
299 a higher number of vesicles formed that are subsequently available for encapsulating drugs,
300 thus providing high stability when compared to the transfersome system²³. Protransfersomes
301 are able to carry active ingredients through the skin pores into the deeper layer. The
302 protransfersome system analyzed in this study has positive characteristics including
303 nanometer size, and thick consistency resulting from its large phospholipid content. When the

304 protransfersome is observed using a light microscope, a palisade lamellar structure appears in
305 the form of liquid crystals. This is due to differences in the degree of hydration of surfactants
306 and phospholipid molecules triggered by solvent limitations. The protransfersome forms as a
307 mixture of flat liquid crystals resembling palisade and vesicular lamellae linked together³⁹.
308 The **percentage of entrapment efficiency (EE%)** of the protransfersome system is a parameter
309 used to predict the stability of the dispersion⁴⁰ describing the amount of drug present in the
310 vesicle⁴¹. In this study, the EE% value was comparatively large because it corresponded to
311 the phospholipid content in the formula⁴² and the tendency of CoQ10 to be retained in the
312 phospholipid membrane due to its lipophilic properties³⁹.

313 To improve acceptability, the protransfersome was formulated as an **emulgel**
314 preparation incorporating the use of an emulgel as the gel base. In this study, three types of
315 **emulgels** were developed and evaluated for their anti-**ageing** and irritability activity, namely;
316 Protransf-CoQ10 **emulgel**, **emulgel** loaded CoQ10 which was previously dissolved in oleic
317 acid (CoQ10-Ole **emulgel**) and CoQ10 dispersed in an **emulgel** base (CoQ10 **emulgel**).

318 During the homogenization method for preparing necessary samples the particle size
319 test involves manual shaking which is considered to closely replicate real-life conditions. The
320 particle size of the **emulgel** loaded Co-Q10 remained in the nanometer range, indicating that
321 adding emulgel base to the particle size of Protransf-CoQ10 had no effect. The particle size
322 of Protransf-CoQ10 **Emulgel** is smaller than that of Protransf-CoQ10 itself. This indicates
323 that the particles have turned into transfersome vesicles because they have been partially
324 hydrated by the presence of water in the **emulgel** base. **The decreased vesicle size of**
325 **protransfersomal CoQ10 after dispersion into the emulgel base is probably due to the**
326 **shearing stress that occurs during the incorporation of Protransf-CoQ10 into hydrated**
327 **Carbopol-based emulgel. This causes the small vesicles formed and the emulgel matrix to be**
328 **adsorbed onto the vesicle surface, preventing vesicle fusion or aggregation^{35,36}, while**

329 spontaneous hydration of protransfersome produces larger vesicles than those resulting from
330 dispersion into emulgel. When compared to the particle sizes of CoQ10-Ole Emulgel and Co-
331 Q10 Emulgel, those of all three emulgels-loaded CoQ10s can be measured in nanometers.
332 The order of particle size from the smallest to the largest is Protransf-CoQ10 Emulgel <
333 CoQ10-Ole Emulgel < Co-Q10 Emulgel. Co-Q10 Emulgel is the largest in size because
334 CoQ10 is only dispersed in the emulgel base, while Protransf-CoQ10 Emulgel and CoQ10-
335 Ole Emulgel had similar particle size and PDI probably due to CoQ10 solubility in Oleic
336 Acid for both formulas⁴³. From the results of the polydispersity index, it is evident that all
337 particles have a uniform size distribution. This indicates that the preparation will be stable
338 during storage because it reduces the tendency for particle aggregation which causes the
339 system to become unstable.

340 A test was carried out to determine the physical stability of Protransf-CoQ10 emulgel
341 when stored at different temperatures, namely; room temperature and colder temperatures for
342 28 days and whether differences in particle size, polydispersity index, and pH existed. There
343 was no significant difference in particle size, polydispersity index, and pH of Protransf-
344 CoQ10 emulgel during the study period.

345 The results of the anti-ageing activity of CoQ10 loaded in emulgel and evaluated for
346 skin collagen density confirmed CoQ10-Ole Emulgel as having the highest percentage of
347 collagen density, followed by Protransf-CoQ10 Emulgel. However, no significant difference
348 existed between these groups ($P>0.05$). These two groups demonstrated significant
349 improvement in collagen density compared with the control group whose subjects had been
350 exposed to UV and who recorded the lowest density value. This is probably due to soluble
351 CoQ10 in Oleic Acid loaded into emulgel had been easily released from emulgel than that of
352 Protransf-CoQ10 Emulgel, which the formation of vesicle during hydration results in
353 semipermeable bilayer membrane as water diffusion-limiting barriers for CoQ10 release. The

354 low collagen density has been known caused by imbalance between collagen synthesis by
355 fibroblasts and collagen degradation of UV irradiation, while collagen synthesis is
356 proportionally relate to fibroblasts resident⁴⁴. Moreover, collagen synthesis by fibroblast will
357 actively occur on the 4th day of 21 days⁴⁵. The faster CoQ10 release from CoQ10 Ole
358 Emulgel will stimulates fibroblast proliferation which increase expression of collagen
359 matrix⁴⁶, while the late CoQ10 release from Protransf-CoQ10 Emulgel will result in delayed
360 effects on fibroblast-stimulated collagen synthesis.

361 On the other hand, the Co-Q10 Emulgel-treated group had similar collagen density to
362 that of normal mice, indicating that UV light damages collagen in the skin dermis. It has been
363 known that UV-irradiation damage dermal collagen and elastin fibers⁴⁷, while CoQ10
364 increased the collagen content through decrease of MMP-1 protein level in mice exposed
365 with UV-B⁴⁸. CoQ10 also promotes the fibroblast proliferation⁴⁹. However, it seems that the
366 fibroblast stimulation process to produce collagen matrix between normal and CoQ10-treated
367 groups is different. This situation differed from that of the group treated with CoQ10 in the
368 emulgels. From these results, it can be concluded that CoQ10 provides protection against the
369 ageing effects of UV rays.

370 The anti-ageing activity test was further evaluated for the number of fibroblasts in the
371 skin tissues. Fibroblasts are cells capable of producing collagen. In this case, the assessed
372 fibroblasts were young and light purple in color. The higher the number of fibroblasts, the
373 more collagen was formed. The results showed that the CoQ10 emulgels had a significantly
374 different number of fibroblasts compared to the control group, with the Protransf-CoQ10
375 Emulgel having the highest number, which was $31.50 \pm 9.48\%$ per field view. This indicates
376 that CoQ10 is able to increase the number of fibroblasts.

377 The safety of these anti-ageing emulgels was further evaluated by an irritancy test. The
378 results indicated that the Protransf-CoQ10 Emulgel produced no signs of irritation in the skin

379 tissues observed, while the CoQ10-Ole Emulgel induced mild skin irritation due to the nature
380 of oleic acid.

381 Protransf-CoQ10 Emulgel has potential as an anti-aging product. However, information
382 is lacking about both the drug release profile and its dermal penetrability which supports the
383 theory that protransfersome and its incorporation into emulgel could prove a useful model for
384 developing skin anti-aging cosmetics. Moreover, both the ability of protransfersome and
385 protransfersomal emulgel to maintain drug stability and the physicochemical properties of the
386 forms of skin dosage need to be evaluated for drug levels during study periods in line with
387 ICH guidelines. Therefore, the product development involved could be comprehensively
388 analyzed.

389

390 **Conclusions**

391 The results of this study indicate that emulgel-loaded protransfersomes, employed as delivery
392 carriers of CoQ10, possess positive physical properties, thereby increasing anti-ageing
393 activity with a low skin irritancy score. Proposing the incorporation of protransfersomal
394 emulgel into cosmetics requires further studies especially on the acceptability test in humans
395 and stability tests for longer storage times. From the results of this study, although the
396 primary nature of CoQ10 severely limits its skin delivery, protransfersome provides potential
397 benefits when used as a delivery system for active cosmetic ingredients within skin ageing
398 therapy.

399

400 **Methods**

401 **Materials**

402 In this study Coenzym Q10 (CoQ10) was obtained from Kangcare Bioindustry Co. Ltd.
403 (Nanjing, China). L- α -Phosphatidylcholine is a product of Sigma-Aldrich (Buchs,

404 Switzerland). Tween 80 and Span 80 were both purchased from Enviro Prima Co. Ltd.
405 (Tangerang, Indonesia). The oleic acid used in this study was acquired from Brataco Co. Ltd.
406 (Surabaya, Indonesia). All other reagents were of the available pharmaceutical and analytical
407 grades.

408

409 **Preparation of CoQ10-loaded protransfersome (Protransf-CoQ10)**

410 The protransfersome was composed of L- α -Phosphatidylcholine, Oleic Acid, and Tween 80
411 as shown in Table 2 and prepared with modifications by the method previously reported by
412 Gupta (2012)¹⁵. Initially, CoQ10 was stirred until completely dissolved in a mixture of oleic
413 acid and Tween 80. Finally, L- α -Phosphatidylcholine was added and stirred until dissolved to
414 produce Protransf-CoQ10.

415

416 **Preparation of emulgel containing CoQ10-loaded protransfersome (Protransf-CoQ10 417 Emulgel)**

418 A CoQ10-loaded protransfersome **emulgel** was prepared by adding the Protransf-CoQ10 to
419 the emulgel base with a final CoQ10 content of 1%. **The emulgel base was produced using**
420 **Carbopol 940 added to a combination of Tween 80 and Span 80 (1:1) to form a homogenous**
421 **emulgel base with the addition of Triethylamine (TEA) to adjust the pH to 6.0 \pm 0.2.**
422 Protransf-CoQ10, CoQ10 solution in oleic acid, and CoQ10 powder were subsequently added
423 to this emulgel base and mixed homogenously to produce Protransf-CoQ10 emulgel, CoQ10-
424 Ole emulgel, and CoQ10 emulgel, respectively.

425

426 **Table 2.** Formulation of CoQ and protransfersomal CoQ10-loaded **emulgels**.

427

Component	Amount in Formula (%)
-----------	-----------------------

	Protransf-CoQ10	CoQ10-Ole	CoQ10
	Emulgel	Emulgel	Emulgel
Coenzyme Q10	1.0	1.0	1.0
L- α -Phosphatidylcholine	24.9	-	-
Oleic Acid	37.2	37.2	-
Tween 80	4.3	4.3	-
Emulgel base	Up to 100.0	Up to 100.0	Up to 100.0

428

429 **Evaluation of physical characteristics**

430 The evaluation of physical characteristics includes particle size, polydispersity index, ζ -
431 potential, microscopic observation, entrapment efficiency, and physical stability during
432 storage.

433 The dispersion of Protransf-CoQ10 into an emulgel base at a weight ratio of 2:1
434 produced Protransf-CoQ10 emulgel whose color changes to brownish orange and the
435 reduction on its pungent odor. Meanwhile, the CoQ10 dissolved in oleic acid (CoQ10-Ole)
436 emulgel had an odorless, jelly-like consistency and was bright orange in color. These
437 characteristics were identical to those of CoQ10 emulgel, although the latter had a more
438 transparent appearance due to the absence of oleic acid from the formula.

439 Evaluation of particle size and ζ -potential were respectively carried out using a Delsa™
440 Nano Submicron Particle Size Analyzer (California, USA) and light scattering and electron
441 scattering methods. Approximately 50mg of CoQ10-loaded protransfersome and **emulgels**
442 were resuspended in 5 mL of 0.9% NaCl. The samples were then prepared using the manual
443 shaking method for five minutes²³. The suspension was further diluted by pipetting 150 μ L of
444 sample and added with 2 mL of deionized water (Otsuka Indonesia, Lawang, Indonesia) for
445 sample measurement.

446 The Protransf-CoQ10 was observed microscopically to evaluate its transformation
447 ability in relation to transfersome vesicles by placing a small amount of sample on a glass
448 slide and covering it with a cover glass. A drop of 0.9% NaCl saline solution was added to
449 the other side of the cover slip's cavity³⁸. The evaluation was conducted using an optical
450 microscope before, during, and after addition of 0.9% NaCl at 400x magnification.

451 The EE% was measured for CoQ10 loaded in protransfersome by means of UV-Vis
452 spectrophotometry¹⁶. Approximately 100mg of Protransf-CoQ10 was weighed, and then
453 hydrated with 2 mL phosphate buffered saline (PBS) pH 7.4 and sonicated for 30 minutes
454 until homogeneous. The suspension formed was then centrifuged at 3,000 rpm for 30 minutes
455 to obtain supernatant and sediment in a 10 mL glass tube. The sample was prepared by taking
456 1.5 mL of supernatant and then dissolved in 2 mL methanol, added to 2 mL PBS pH 7.4 and,
457 finally, sonicated for 15 minutes. The sediment was dissolved in 1.5 mL methanol, added to 2
458 mL of PBS and sonicated for 15 minutes. The absorbance of each sample was measured by
459 UV-Vis spectrophotometry at a wavelength of 275 nm. The EE% of CoQ10-loaded in
460 protransfersome was calculated by means of the following equation:

461

$$462 \quad \% EE = \frac{CoQ10 \text{ levels in supernatant}}{CoQ10 \text{ levels in supernatant} + CoQ10 \text{ levels in sediment}} \times 100 \% \quad (\text{Eq. 1})$$

463

464 In order to evaluate whether any chemical or physical changes occurred in samples,
465 spectroscopical and thermal analysis were further investigated. The spectroscopical analysis
466 was evaluated using a Fourier Transformed Infra-Red analysis by using Spectrophotometer
467 ECO ATRS Bruker Alpha II (Germany). About 1 mg sample was analyzed at wavenumbers
468 of 450 to 4000 cm^{-1} . While, the thermal analysis was evaluated using *Differential Thermal*
469 *Analysis* (DTA) instrument (Mettler Toledo FP 85, Switzerland). About 3-5 mg samples was

470 put into crucible sample pan. The sample was then subsequently heated from 30 to 300°C at a
471 heating rate of 10°C per minutes.

472 Moreover, a stability test of the Protransf-CoQ10 emulgel was carried out by storing
473 the samples at in the dark at room temperature ($24 \pm 2^\circ\text{C}$) and, subsequently, a cold
474 temperature ($4 \pm 2^\circ\text{C}$) for 28 days⁵⁰⁻⁵². The emulgel was evaluated for physical
475 characteristics, i.e., pH and particle size, on the 28th day after preparation.

476

477 **In vivo study of anti-ageing in UV-rays ageing induced mice**

478 The *in vivo* anti-ageing activity was evaluated using Balb/c mice (*Mus musculus*) within the
479 terms of a study protocol approved by The Ethics Commission of Faculty of Veterinary
480 Medicine, Universitas Airlangga (Certificate number 2.KE.016.02.2020 dated February 4,
481 2020). All methods were performed in accordance with ARRIVE guidelines and relevant
482 regulations⁵³. Within this research, two types of study involving the uses of experimental
483 models were evaluated, firstly, anti-ageing activity as indicated by collagen density and
484 number of fibroblasts, and, secondly, a safety test incorporating irritancy scoring of skin
485 tissue. The effect of the Protransf-CoQ10 emulgel was compared with those of CoQ10-Ole
486 and CoQ10 emugels. Each group comprises of 4 mice as the study model. Prior to the study,
487 the hair on the models' backs was trimmed with mechanical hair clippers, ensuring that their
488 skin was not injured during this process. Each model was housed in a separate cage to
489 prevent their touching the part to be smeared with the sample.

490

491 ***Anti-ageing Activity Test***

492 The anti-ageing activity test was evaluated to establish the parameters of collagen fiber
493 density and the number of fibroblasts. The study was carried out by applying 200 mg of the
494 emulgels twice a day every day to a 4 cm² area of previously shaved skin on the models'

495 backs. The sample was applied 20 minutes before UV irradiation, in order to provide time for
496 absorption into the skin, and four hours after irradiation which is the point at which the
497 formation of Reactive Oxygen Species commences. An 80 mJ/cm² dose of UV light was
498 administered at an irradiation distance of 15 cm for 21 minutes. UV irradiation was carried
499 out once every two days, namely; on days 1, 3, 5, 7, 9, 11, and 13, with the models
500 subsequently being left for 24 hours on completion of the irradiation process to overcome the
501 effects of acute irradiation⁵⁴. Sample application was also conducted on days when the
502 models were not exposed to UV irradiation. After 14 days, the models were sacrificed by
503 dislocation with the skin tissues being subsequently excised to produce a tissue section using
504 a microtome. To evaluate the collagen density, the tissue section was stained with Masson
505 trichrome staining, while for the observation of fibroblasts, the skin tissue section was stained
506 with Hematoxylin-Eosin Staining. The tissue section was then observed with a light
507 microscope (Olympus CX 31 Camera DP 22) using Cellsen Standard Software. Collagen
508 density was measured by histochemical scoring, while the number of fibroblasts was
509 calculated by digital analysis using Adobe Photoshop and Image J software. Density
510 measurement involved measuring the area of collagen coir and comparing it with the field of
511 view. The denser the coir collagen, the higher the density value, and vice versa. Calculation
512 of the density value was completed by means of calculating the area of the field of view and
513 the black colored area using Image J software calibrated fin advance or each degree of
514 magnification. The comparison of the black stained area with the field of view produced the
515 density value.

516

517 ***In vivo* skin irritancy evaluation of proransfersome loaded CoQ10 in emulgels**

518 In order to observe the irritant effects of CoQ10-loaded in proransfersome and emulgels,
519 histopathological changes in the skin tissues of each model after a 24-hour period of exposure

520 were observed. Firstly, the back hair of the models had been shaved. Approximately 200 mg
521 of the sample was then applied to a 2x2 cm² area of skin on their backs. Twenty-four hours
522 after application, the models were sacrificed by dislocation. Skin was excised with a
523 microtome before being immersed in a formalin solution and stained with hematoxylin-eosin.
524 The preparations were observed with a light microscope to assess the degree of skin irritation
525 by means of histopathological scoring. Histological change data is semi-qualitative and
526 features five variables, namely; epidermis liquefaction, subepidermal edema, collagen fiber
527 swelling, inflammatory cell infiltration, and degeneration of the appendages in hair vesicles.
528 The scoring method comprised a score of 0 = normal skin, 1 = mild irritation, 2 = moderate
529 irritation, and 3 = severe irritation⁵⁵. The data from each sample consisted of the mean value
530 of the variable score for each of the five different fields of view at 100x and 400x
531 magnification. All examinations involved the use of an ordinary light microscope (Nikon
532 H600L, equipped with a 300 megapixel DS Fi2 digital camera and Nikkon Image System
533 image processing software).

534

535 **Statistical analysis**

536 The data in this study consisted of three replicates. In order to test the significance of
537 differences in the data relating to Protransf-CoQ10 emulgel, CoQ10-Ole emulgel, and CoQ10
538 emulgel, a statistical analysis was performed using the one-way variant analysis (ANOVA)
539 method. After the normality and homogeneity of the data had been tested, a Post Hoc Tukey
540 HSD test was administered. If the *P value* < 0.05, then a significant difference between the
541 results of the tests performed existed. However, if the data was not normally distributed and
542 homogeneous, the data would be analyzed using non-parametric statistics by means of the
543 Kruskall Wallis method and, subsequently, a Post Hoc Mann Whitney U test. If the *P value* <
544 0.05; then a significant difference existed.

545

546

547 **References**

- 548 1. Schniertshauer, D., Gebhard, D. & Bergemann, J. Age-Dependent Loss of
549 Mitochondrial Function in Epithelial Tissue Can Be Reversed by Coenzyme Q10. *J.*
550 *Aging Res.* **2018**, (2018).
- 551 2. Baumann, L. Skin ageing and its treatment. *J. Pathol.* **211**, 241–251 (2007).
- 552 3. Knott, A. *et al.* Topical treatment with coenzyme Q10-containing formulas improves
553 skin 's Q10 level and provides antioxidative effects. *Biofactor* **41**, 383–390 (2015).
- 554 4. Rinnerthaler, M., Bischof, J., Streubel, M. K., Trost, A. & Richter, K. Oxidative Stress
555 in Aging Human Skin. *Biomolecules* **5**, 545–589 (2015).
- 556 5. Shin, J. W. *et al.* Molecular mechanisms of dermal aging and antiaging approaches.
557 *Int. J. Mol. Sci.* **20**, (2019).
- 558 6. Ganceviciene, R., Liakou, A. I., Theodoridis, A., Makrantonaki, E. & Zouboulis, C. C.
559 Skin anti-aging strategies. *Dermatoendocrinol.* **4**, (2012).
- 560 7. Valko, M. *et al.* Free radicals and antioxidants in normal physiological functions and
561 human disease. *Int. J. Biochem. Cell Biol.* **39**, 44–84 (2007).
- 562 8. Inui, M. *et al.* Mechanisms of inhibitory effects of CoQ 10 on UVB-induced wrinkle
563 formation in vitro and in vivo. *BioFactors* **32**, 237–243 (2008).
- 564 9. Bank, G., Kagan, D. & Madhavi, D. Bank, G.,*et al.*,2010.Coenzyme Q10: Clinical
565 Update and Bioavailability.pdf. 6 (2011). doi:10.1177/2156587211399438
566 <http://cam.sagepub.com>
- 567 10. Vaghari, H., Vaghari, R., Jafarizadeh-Malmiri, H. & Berenjian, A. Coenzyme Q10 and
568 its effective sources. *Am. J. Biochem. Biotechnol.* **12**, 214–219 (2016).
- 569 11. Shoviantari, F., Erawati, T. & Soeratri, W. Skin Penetration of Coenzyme Q10 in
570 Nanostructure Lipid Carriers Using Olive Oil and Cetyl Palmitate. *Int. J. Pharm. Clin.*
571 *Res.* **9**, 142–145 (2017).

- 572 12. Wang, J. *et al.* Physicochemical characterization, photo-stability and cytotoxicity of
573 coenzyme Q10-loading nanostructured lipid carrier. *J. Nanosci. Nanotechnol.* **12**,
574 2136–2148 (2012).
- 575 13. Iskandarsyah, Rahmi, A. D. & Pangesti, D. M. Comparison of the characteristics of
576 transfersomes and protransfersomes containing azelaic acid. *J. Young Pharm.* **10**, s11–
577 s15 (2018).
- 578 14. Jain, S., Sapre, R., Umamaheswari, R. B. & Jain, N. K. Protransfersomes for effective
579 transdermal delivery of norgestrel preparation and in vitro characterization. *Indian*
580 *Journal of Pharmaceutical Sciences* **65**, 152–160 (2003).
- 581 15. Gupta, V. & Trivedi, P. Enhancement of storage stability of cisplatin-loaded
582 protransfersome topical drug delivery system by surface modification with block
583 copolymer and gelling agent. **22**, 361–366 (2012).
- 584 16. Sayali, T. Makarand, G. Kishor, G. Formulation and Development of Ketorolac
585 Tromethamine Protransfersomal Gel. *Int. J. Institutional Pharm. Life Sci.* **5**, 411–428
586 (2015).
- 587 17. Chaurasiya, P., Ganju, E., Upmanyu, N., Ray, S. K. & Jain, P. Transfersomes: a novel
588 technique for transdermal drug delivery. *J. Drug Deliv. Ther.* **9**, 279–285 (2019).
- 589 18. Premchandani, L. A. *et al.* Formulation of Protransfersomal Gel of Diclofenac
590 Potassium and Its in-Vitro Characterization. *Indian J. Drugs* **4**, 129–140 (2016).
- 591 19. Rai, S., Pandey, V. & Rai, G. Transfersomes as versatile and flexible nano-vesicular
592 carriers in skin cancer therapy: the state of the art.pdf. (2017).
- 593 20. Sala, M., Diab, R., Elaissari, A. & Fessi, H. Lipid nanocarriers as skin drug delivery
594 systems: Properties, mechanisms of skin interactions and medical applications. *Int. J.*
595 *Pharm.* **535**, 1–17 (2018).
- 596 21. Chen, S., Hanning, S., Falconer, J., Locke, M. & Wen, J. Recent advances in non-ionic

- 597 surfactant vesicles (niosomes): Fabrication, characterization, pharmaceutical and
598 cosmetic applications. *Eur. J. Pharm. Biopharm.* **144**, 18–39 (2019).
- 599 22. Gupta, V., Dhote, V., Paul, B. N. & Trivedi, P. Development of novel topical drug
600 delivery system containing cisplatin and imiquimod for dual therapy in cutaneous
601 epithelial malignancy. *J. Liposome Res.* **24**, 150–162 (2014).
- 602 23. Miatmoko, A., Kawano, K., Hattori, Y., Maitani, Y. & Yonemochi, E. Y. Evaluation
603 of Transfersome and Protransfersome for Percutaneous Delivery of Cisplatin in
604 Hairless Mice. *J. Pharm. Pharmacol.* (2015).
- 605 24. Caddeo, C. *et al.* Tocopherol-loaded transfersomes : In vitro antioxidant activity and
606 efficacy in skin regeneration. *Int. J. Pharm.* **551**, 34–41 (2018).
- 607 25. Kommuru, T. R., Gurley, B., Khan, M. A. & Reddy, I. K. Self-emulsifying drug
608 delivery systems (SEDDS) of coenzyme Q10: formulation development and
609 bioavailability assessment. *Int. J. Pharm.* **212**, 233–246 (2001).
- 610 26. Sguizzato, M. *et al.* Ethosomes for Coenzyme Q10 Cutaneous Administration : From
611 Design to 3D Skin Tissue Evaluation. *antioxidants* **9**, 485 (2020).
- 612 27. El-Zaafarany, G. M., Abdel-Aziz, R. T. A., Montaser, M. H. A. & Nasr, M. Coenzyme
613 Q10 phospholipidic vesicular formulations for treatment of androgenic alopecia: ex
614 vivo permeation and clinical appraisal. *Expert Opin. Drug Deliv.* 1–9 (2021).
615 doi:10.1080/17425247.2021.1936497
- 616 28. Ryu, K. A. *et al.* Topical delivery of coenzyme Q10-loaded microemulsion for skin
617 regeneration. *Pharmaceutics* **12**, (2020).
- 618 29. Sigma Aldrich. Product Information: L- α -phosphatidylcholine. 1–2 (2018).
- 619 30. Bandarra, N. M., Campos, R. M., Batista, I., Nunes, M. L. & Empis, J. M. Antioxidant
620 synergy of α -tocopherol and phospholipids. *JAACS, J. Am. Oil Chem. Soc.* **76**, 905–
621 913 (1999).

- 622 31. Cui, L. & Decker, E. A. Phospholipids in foods: Prooxidants or antioxidants? *J. Sci.*
623 *Food Agric.* **96**, 18–31 (2016).
- 624 32. Kamaraj, N., Rajaguru, P. Y., Issac, P. & Sundaresan, S. Fabrication , characterization
625 , in vitro drug release and glucose uptake activity of 14-deoxy , 11 , 12-
626 didehydroandrographolide loaded polycaprolactone nanoparticles. *Asian J. Pharm. Sci.*
627 **12**, 353–362 (2017).
- 628 33. Miatmoko, A. *et al.* Interactions of primaquine and chloroquine with PEGylated
629 phosphatidylcholine liposomes. *Sci. Rep.* 1–12 (2021). doi:10.1038/s41598-021-
630 91866-0
- 631 34. Budiman, A. Characterization of drugs encapsulated into mesoporous silica. *Int. J.*
632 *Appl. Pharm.* **11**, 7–11 (2019).
- 633 35. Gupta, V. & Trivedi, P. Enhancement of storage stability of cisplatin-loaded
634 protransfersome topical drug delivery system by surface modification with block
635 copolymer and gelling agent. *J. Drug Deliv. Sci. Technol.* **22**, 361–366 (2014).
- 636 36. Gupta, V. & Trivedi, P. Ex vivo localization and permeation of cisplatin from novel
637 topical formulations through excised pig , goat , and mice skin and in vitro
638 characterization for effective management of skin- cited malignancies Ex vivo
639 localization and permeation of cisplatin. *Artificial Cells, Nanomedicine, Biotechnol.* **43**,
640 373–382 (2015).
- 641 37. Ibrahim, M. M., Nair, A. B., Aldhubiab, B. E. & Shehata, T. M. Hydrogels and Their
642 Combination with Liposomes, Niosomes, or Transfersomes for Dermal and
643 Transdermal Drug Delivery. *Liposomes* (2017). doi:10.5772/intechopen.68158
- 644 38. Miatmoko, A., Kawano, K., Hattori, Y., Maitani, Y. & Yonemochi, E. Evaluation of
645 transfersome and protransfersome for percutaneous delivery of cisplatin in hairless
646 mice. *J Pharmaceu Pharmacol S*, 1–7 (2015).

- 647 39. Jain, S., Sapre, R., Tiwary, A. K. & Jain, N. K. Proultraflexible lipid vesicles for
648 effective transdermal delivery of levonorgestrel: Development, characterization, and
649 performance evaluation. *AAPS PharmSciTech* **6**, (2005).
- 650 40. Singh, M., Issarani, R., Nagori, B. P., Singh, N. & Singh, M. K. Development and
651 Characterization of Timolol Maleate Loaded Protransfersomal Gel. *Adv. Sci. Focus* **1**,
652 211–219 (2013).
- 653 41. Morsi, N. M., Aboelwafa, A. A. & Dawoud, M. H. S. Enhancement of the
654 bioavailability of an antihypertensive drug by transdermal protransfersomal system:
655 formulation and in vivo study. *Journal of Liposome Research* **28**, 137–148 (2018).
- 656 42. Premchandani, L. A., Bakliwal, S. R. & Dhankani, A. R. Formulation of
657 Protransfersomal Gel of Diclofenac Potassium. *Indian J. Drugs* **4**, 129–140 (2016).
- 658 43. Seo, D. W., Kang, M. J., Sohn, Y. S. & Lee, J. Self-microemulsifying Formulation-
659 based Oral Solution of Coenzyme Q10. *Yakugaku Zasshi* **129**, 1559–1563 (2009).
- 660 44. Varani, J. *et al.* Decreased Collagen Production in Chronologically Aged Skin Roles of
661 Age-Dependent Alteration in Fibroblast Function and. *Am. J. Pathol.* **168**, 1861–1868
662 (2006).
- 663 45. Syahputra, D. A., Kusmayadi, D. D. & Hernowo, B. S. Effect of mechanical bowel
664 preparation in fibroblast , collagen density and histopathology analysis in colon
665 anastomosis site of Wistar rat. *Bali Med. J.* **9**, 110–114 (2020).
- 666 46. Zhang, M. *et al.* Coenzyme Q(10) enhances dermal elastin expression, inhibits IL-1 α
667 production and melanin synthesis in vitro. *Int. J. Cosmet. Sci.* **34**, 273–279 (2012).
- 668 47. Li, X., Matsumoto, T., Takuwa, M., Saeed, M. & Shaiku, E. Protective Effects of
669 Astaxanthin Supplementation against Ultraviolet - Induced Photoaging in Hairless
670 Mice. *Biomedicines* **8**, 18 (2020).
- 671 48. Wu, H. *et al.* Coenzyme Q(10) Sunscreen Prevents Progression of Ultraviolet-Induced

- 672 Skin Damage in Mice. *Biomed Res. Int.* **2020**, 9039843 (2020).
- 673 49. Muta-Takada, K. *et al.* Coenzyme Q10 protects against oxidative stress-induced cell
674 death and enhances the synthesis of basement membrane components in dermal and
675 epidermal cells. *BioFactors* **35**, 435–441 (2009).
- 676 50. Bragagni, M., Mennini, N., Maestrelli, F., Cirri, M. & Mura, P. Comparative study of
677 liposomes, transfersomes and ethosomes as carriers for improving topical delivery of
678 celecoxib. *Drug Deliv.* **19**, 354–361 (2012).
- 679 51. Modi, C. . & Bharadia, P. Transfersomes: New Dominants for Transdermal Drug
680 Delivery. *Am. J. pharmTech Res. AJPTR.* **2**, 71–91 (2012).
- 681 52. Annisa, R., Mutiah, R., Hakim, A. & Rahmadiyah, D. N. K. Formulation design and
682 evaluation of hydrocortisone-loaded nanoemulsion and nanoemulsion gel for topical
683 delivery. *AIP Conf. Proc.* **2120**, (2019).
- 684 53. Percie du Sert, N. *et al.* Reporting animal research: Explanation and elaboration for the
685 ARRIVE guidelines 2.0. *PLOS Biol.* **18**, e3000411 (2020).
- 686 54. Vayalil, P. K., Elments, C. A. & Katiyar, S. K. Treatment of green tea polyphenols in
687 hydrophilic cream prevents UVB-induced oxidation of lipids and proteins, depletion of
688 antioxidant enzymes and phosphorylation of MAPK proteins in SKH-1 hairless mouse
689 skin. *Carcinogenesis* **24**, 927–936 (2003).
- 690 55. Klopfleisch, R. Multiparametric and semiquantitative scoring systems for the
691 evaluation of mouse model histopathology - a systematic review. *BMC Vet. Res.* **9**, 1
692 (2013).

693

694

695 **Acknowledgements**

696 None

697

698 **Author Contributions**

699 **Qurrota Ayunin:** 1) conception and design of the work, data acquisition, data analysis and
700 interpretation; 2) Drafting the article; 3) Final approval of the version to be published; 4)
701 Agreement to be accountable for all aspects of the work in ensuring that questions related to
702 the accuracy or integrity of the work are appropriately investigated and resolved.

703 **Andang Miatmoko:** 1) conception and design of the work, data acquisition, data analysis
704 and interpretation; 2) critically revising the article for important intellectual content; 3) Final
705 approval of the version to be published; 4) Agreement to be accountable for all aspects of the
706 work in ensuring that questions related to the accuracy or integrity of the work are
707 appropriately investigated and resolved.

708 **Widji Soeratri:** 1) data analysis and interpretation; 2) critically revising the article for
709 important intellectual content; 3) Final approval of the version to be published; 4) Agreement
710 to be accountable for all aspects of the work in ensuring that questions related to the accuracy
711 or integrity of the work are appropriately investigated and resolved.

712 **Tristiana Erawati:** 1) data analysis and interpretation; 2) Final approval of the version to be
713 published; 3) Agreement to be accountable for all aspects of the work in ensuring that
714 questions related to the accuracy or integrity of the work are appropriately investigated and
715 resolved.

716 **Joni Susanto:** 1) data analysis and interpretation; 2) Final approval of the version to be
717 published; 3) Agreement to be accountable for all aspects of the work in ensuring that
718 questions related to the accuracy or integrity of the work are appropriately investigated and
719 resolved.

720 **Djoko Legowo:** 1) data analysis and interpretation; 2) Final approval of the version to be
721 published; 3) Agreement to be accountable for all aspects of the work in ensuring that
722 questions related to the accuracy or integrity of the work are appropriately investigated and
723 resolved.

724

725

726 **Financial Disclosures**

727 None

728

729 **Ethical Conduct of Research Statement**

730 The animal study procedures were performed in accordance with the ethical clearance issued
731 by The Ethics Commission of Faculty of Veterinary Medicine, Universitas Airlangga
732 (Certificate number 2.KE.016.02.2020 dated February 4, 2020)

733

734 **Competing Interest**

735 The authors declare no competing interest

736

737 **Figure Legends**

738

739 **Figure 1.** Lamellar structure of liquid crystals of the CoQ10 protransfersome emulgel after
740 adding one drop of saline under an optical microscopy observation at 400x magnification
741 (Scale bar:100 μm).

742

743 **Figure 2.** Visual appearance of protransfersomal CoQ10 (Protransf-CoQ10) (A), emulgel
744 base (B), protransfersomal CoQ10 (Protransf-CoQ10) Emulgel (C), CoQ10 dissolved in oleic
745 acid (CoQ10-Ole) Emulgel (D), and CoQ10 loaded in emulgel (CoQ10 Emulgel) (E). The
746 Intensity distribution of particle of protransfersomal CoQ10 (Protransf-CoQ10) Emulgel (F),
747 CoQ10 dissolved in oleic acid (CoQ10-Ole) Emulgel (G), and CoQ10 loaded in emulgel
748 (CoQ10 Emulgel) (H).

749

750

751 **Figure 3.** Fourier-transform infrared spectra of Coenzyme Q10 (CoQ10), Blank
752 protransfersome, and protransfersome loaded CoQ10 (Protransf-CoQ10).

753

754 **Figure 4.** Differential thermal analysis of Coenzyme Q10 (CoQ10), L- α -Phosphatidylcholine
755 as phospholipid component of protransfersome, and protransfersome loaded CoQ10
756 (Protransf-CoQ10).

757

758 **Figure 5.** Evaluation of particle size, polydispersity index, and pH stability of
759 protransfersomal CoQ10 loaded in emulgel (Protransf-CoQ10 Emulgel) during 28 days
760 stored at room ($25\pm 2^\circ\text{C}$) and cool ($4\pm 2^\circ\text{C}$) temperatures.

761

762 **Figure 6.** The collagen density of dermis layer of subject's back skin without and with UV-
763 induced photoageing after topically applied with saline (Normal skin and UV-induced skin),
764 CoQ10-loaded emulgel, CoQ10 dissolved in oleic acid (CoQ10-Ole) Emulgel, and
765 protransfesomal CoQ10 (Protransf-CoQ10) Emulgel once every two days for two weeks.
766 * $P < 0.05$ compared to UV-induced skin, # $P < 0.05$ compared to Normal Skin.

767

768 **Figure 7.** The number of fibroblasts of mice back skin without and with UV-induced
769 photoageing after topically applied with saline (Normal skin and UV-induced skin), CoQ10-
770 loaded emulgel, CoQ10 dissolved in oleic acid (CoQ10-Ole) Emulgel, and protransfesomal
771 CoQ10 (Protransf-CoQ10) Emulgel once every two days for two weeks. * $P < 0.05$ compared
772 to UV-induced skin, # $P < 0.05$ compared to Normal Skin, \$ $P < 0.05$ compared to CoQ10-Ole
773 treated skin.

774

775 **Figure 8.** The histopathology of mice back skin stained with Hematoxylin-Eosin without and
776 with UV-induced photoageing at 24 hours after topically applied with saline (Normal skin
777 and UV-induced skin), CoQ10-loaded Emulgel, CoQ10 dissolved in oleic acid (CoQ10-Ole)
778 Emulgel, and protransfesomal CoQ10 (Protransf-CoQ10) Emulgel.

779

780 **Figure 9.** The scoring results of histopathology of mice back skin s without and with UV-
781 induced photoageing at 24 hours after topically applied with saline (Normal skin and UV-
782 induced skin), CoQ10-loaded Emulgel, CoQ10 dissolved in oleic acid (CoQ10-Ole) Emulgel,
783 and protransfesomal CoQ10 (Protransf-CoQ10) Emulgel.

784

785

786 **Table Legends**

787 **Table 1.** Particle Size and polydispersity index of CoQ10 loaded in emulgel (CoQ10
788 Emulgel), CoQ10 dissolved in oleic acid (CoQ10-Ole) Emulgel, and protransfersomal CoQ10
789 (Protransf-CoQ10) Emulgel. Each value represents the mean \pm SD (n = 3).

790

791 **Table 2.** Formulation of CoQ and protransfersomal CoQ10-loaded emulgels.

792

793

1. Answer:

However, the use of optical microscopy, under plain and polarized light, is generally used for detecting liquid lamellar crystalline of protransfersome as reported in Jain et al., 2003 and Vora et al, 1998. In the study of physical characteristics of protransfersome, the photomicrography analysis is intended to observe before and after in situ hydration as a proof that the vesicle formation has occurred.

4.answer:

In addition, there probably oxidation caused by air exposure occurred during the preparation causing darkening color of the Protrans-CoQ10 loaded in emulgel, as we have no use of antioxidant on the formula. It has been reported that L- α -phosphatidylcholine can be more easily oxidized preventing free radicals bad effects to drugs (Bandarra *et al.* 1999; Cui and Decker 2016).

Line 148-150: We have added a sentence into the paragraph: “The darkening color of Protransf-CoQ10 gel probably due to large amount of L- α -Phosphatidylcholine content of which has dark yellow color(Sigma Aldrich 2018) and easily oxidized when it is exposed to air in for long periods (Bandarra *et al.* 1999; Cui and Decker 2016).”

4. Answer:

Regarding the concentration of CoQ10 in this formula, there was about 1%w/w, which is actually sufficient for analysis. On the other hand, CoQ10 encapsulation into protransfersome probably responsible for peak disappearance of CoQ10 in the Protransf-CoQ10 spectra profile, which makes it similar to that of Protransfersome blank, as previously reported. In addition, it may be the interaction occurs physically, with less or no chemical interaction causing no appearance of peak absorbances were observed (Kamaraj *et al.* 2017a; Miatmoko *et al.* 2021)

Miatmoko et al., 2021 reported that specific peak of Primaquine and Chloroquine were disappeared due to their encapsulation into inner phase of liposomes. Other reports also showed that if there are physical interactions between drugs and mesoporous silica, the spectra of drug will decrease or less sharp compared with native drug (Budiman 2019).

“This result indicates that CoQ10 successfully encapsulated into protransfersome and no chemical interaction occurred in the mixtures (Kamaraj *et al.* 2017b; Budiman 2019; Miatmoko *et al.* 2021).”

5. Answer:

In this study, protransfersomal gel mask refers to semisolid emulgel formulation contained protransfersome intended use for facial mask purpose, while the normal protransfersome gel is similar to this gel mask either as emulgel or hydrophilic gel, which only requires gelling agents; however, there are some others main functional components of gel mask are required, such as moisturizers, fragrance, etc. However, this study is still the initial research for developing gel mask, which we intend to produce such products for, therefore, we replaced the use of “gel mask” terms in the manuscript.

6. Answer:

Many thanks for the comments. Emulgel is an emulsion transformed to a gel by gelling agent” (Ibrahim *et al.* 2017), therefore in this manuscript we used term emulgel due to the addition of emulgators or surfactants, in addition to gelling agent, to stabilize Protransfersome-CoQ10 dispersion. During pre-formulation study, without emulgators addition, the gel was unstable indicated by separation of oil phase due to large amount of hydrophobic oleic acid, which was about 37% in the final weight of protransfersomal gel. The gelling agent used is Carbopol, a methacrylate polymer that has been widely used for topical gel due to its acceptable textures and rigid consistency in neutral pH. The Carbopol itself could entrap oil phase in little amount, however when the amount is getting high, its hydrophilic nature could not stabilize the system, therefore the use of emulgator is urgently required. After adding some emulgators, the gel was stably formed and more acceptable due to watery consistency of this protransfersomal gel.

7. Answer:

Line 37-39: “The *in vivo* studies of anti-ageing activity and irritability were further evaluated by applying 200 mg of the emulgels twice a day every day to a 4 cm² back area of UV-ray age-induced male Balb/c mice at 20 minutes before irradiation.”

Reviewer 2

1. Answer:

Line 368-371: we have added a sentence as the following: “The emulgel base was produced by using Carbopol 940 added with a combination of Tween 80 and Span 80 (1:1) to form a homogenous emulgel base with addition of Triethylamine (TEA) for adjusting pH to 6.0 ± 0.2 .”

3. Answer:

According to ICH guideline, there are accelerated, immediate and long term stability study, which requires 0, 3, and 6 months for accelerated test. However, we referred to other reports regarding development transfersomes and ethosomes which were stored at 4°C and at room temperature (25°C) for 30 days, and monitored every 10 days for physical stability (visual observation and mean size determination) and for drug entrapment efficacy and drug (Bragagni *et al.* 2012). Other reports also evaluated physical stability test including organoleptic testing (discoloration, odor, phase separation and clarity) and pH of the preparation at the room temperature ($28^{\circ}\text{C} \pm 2^{\circ}\text{C}$), high temperature ($40^{\circ}\text{C} \pm 2^{\circ}\text{C}$), and low temperature ($4^{\circ}\text{C} \pm 2^{\circ}\text{C}$) for two weeks (Annisa *et al.* 2019). Therefore, in this study, to determine the stability of protransfersomal emulgels, we evaluated the physical stability for 28 days at cool and room temperature.

4. Answer:

Regarding this result, the presence of surfactant i.e. Tween 80 and Span 80 in the emulgel base may contribute to particle reduction of insoluble CoQ10, however we have no data of COQ10 dispersed in Carbopol base gel to support this opinion. Although CoQ10

particle had size in nanometer, its high hydrophobicity would prevent its penetration to dermis, as well as low stability protection against oxidation thus causing low efficacy in antiageing study in UV-irradiated mice.

5. Answer:

Regarding the similar particle size of CoQ10-Ole Emulgel to Protransf-CoQ10 Emulgel, it could be due to CoQ10 was dissolved in Oleic Acid contained in both emulgels, thus making the particle size is defined by Oleic acid dispersion in the emulgel base.

Line 312-314: while Protransf-CoQ10 Emulgel and CoQ10-Ole Emulgel had similar particle size, as well as PDI probably due to CoQ10 solubility in Oleic Acid for both formulas(Seo *et al.* 2009).

6. Answer:

Line 308-314: “The decreased vesicle size of protransfersomal CoQ10 after dispersion into the emulgel base probably be due to the shearing stress occurs during incorporation Protransf-CoQ10 into hydrated Carbopol-based emulgel causing the vesicle formed into small size and the emulgel matrix would adsorbed onto the vesicle surface, preventing vesicle fusion or aggregation (Gupta and Trivedi 2014, 2015); while, spontaneous hydration of protransfersome produce vesicle in larger size than that of dispersion into emulgel.”

7. Answer:

Increasing stability of CoQ10 referring to its entrapment into protransfersome, which hydrophobic molecules of CoQ10 would be entrapped within hydrophobic stack of phospholipids in protransfersome system, or when protransfersome transforms into transfersome vesicle due to water hydration in emulgel, CoQ10 will be entrapped within hydrophobic bilayer membrane, thus preventing direct oxidation against free oxygen. However, in this study, we have not determined yet the level of CoQ10 after storage. In addition, the zeta potentials reflect the stability of vesicle-vesicle and vesicle-medium interaction; also predict the tendency of particle to aggregate. However, the incorporation into carbopol emulgel matrix have been proven to improve vesicle physical stability (Gupta and Trivedi 2014, 2015), thus the zeta potential actually less significantly affects it. On the other hand, the low value of zeta potential provide advantages for improved skin penetration of the vesicles (Gillet *et al.* 2011).

8. Answer:

The use of surfactants in this study is intended to form emulgel, with Carbopol as the gelling agent. Emulgel is an emulsion transformed to a gel by gelling agent (Ibrahim *et al.* 2017), therefore in this study, the addition of emulgators or surfactants, in addition to gelling agent, is intended to stabilize Protransfersome-CoQ10 dispersion. During pre-formulation study, without surfactants addition, the gel was unstable indicated by separation of oil phase due to large amount of hydrophobic oleic acid, which was about 37% in the final weight of protransfersomal gel. The gelling agent used is Carbopol, a methacrylate polymer that has been widely used for topical gel due to its acceptable textures and rigid consistency in neutral pH. The Carbopol itself could entrap oil phase in

little amount, however when the amount is getting high, its hydrophilic nature could not stabilize the system, therefore the use of surfactant is urgently required. However, to produce stable emulgel system, we calculated the Hydrophilic-Lipophilic Balance (HLB) value by considering the oil and water phase, thus making us to use both hydrophilic and lipophilic surfactants. After adding these surfactants, the gel was stably formed and more acceptable due to watery consistency of this protransfersomal gel.

9. Answer:

The entrapment efficiency of some hydrophobic drugs into transfersome could be high if the drug ratio used is low, generally less than 10% molar ratio to the total lipid. Even though, in many cases, according to the previous study we used, hydrophobic drug encapsulation into transfersome only provide no more than 30% of drug encapsulation. On the other hand, encapsulation of hydrophilic drugs such as doxorubicin into liposomal vesicle could produce almost 100% of drug encapsulation by active loading at drug to lipid ratio of 1:5.

Adding drugs into protransfersome successfully increase the amount of encapsulated drugs, without any drug precipitation occurs, as shown in our previous study (Miatmoko *et al.* 2015). In general, transfersome contains total lipid, including phospholipids and surfactants, of 8 mg/mL, which increasing the total lipid will cause lipid or vesicles tend to aggregate, while for protransfersome, it can be formulated up to 50 mg total lipid per mL, which much higher than that of transfersome.

Line 292-296: Protransfersomes have been developed as the nanometer-sized carrier form of provesicle of transfersome and have a higher phospholipid content compared to transfersomes. This enables the protransfersome system to have a higher entrapment efficiency due to more number of vesicles formation encapsulating drugs, thus providing high stability when compared to the transfersome system (Miatmoko *et al.* 2015).

10. Answer:

In this evaluation, we prepared the samples with three replications, and then we divided them for each storage conditions. The differences in size and pH at day 0 occurred because we measured each sample, thus the data reflects variations of measurement.

12. Answer:

The main purpose of protransfersome formulation is to highly encapsulate CoQ10, which is intended to modify physicochemical characteristics of CoQ10, making it to more water dispersible and easily penetrate the skin since high lipophilic CoQ10 has low water solubility and poor skin penetration. However, the high use of Oleic Acid in protransfersome would cause unacceptable daily use for skin cosmetics; therefore, we further added it into emulgel, to produce high acceptance for use. In the functional aspects of vesicle, the formation of transfersome due to hydration of protransfersome by water content in emulgel base still results in ultradeformable vesicles which allow them to easily penetrate across the skin.

In addition, previous reports showed that the presence of gelling agent would act as steric hindrance which will be adsorbed onto vesicle surface preventing fusion or aggregation thus increasing physical stability during storage (Gupta and Trivedi 2014, 2015). The addition of lipid vesicles into gel are beneficials for increasing vesicle stability, prolonging drug release, improving dermal permeability, and enhance drug deposition in skin (Ibrahim *et al.* 2017).

13. Answer:

Previously, the product is intended to be used as a facial mask for anti-ageing, however, regarding the use as mask, we have no data support it in this study. Therefore, we replaced the word of mask with emulgel, for general use.

14. Answer:

Surely we agree that the drug release profile would determine the delivery of drug to target site, however, in this study, we focused on the use of protransfersome as deformable vesicle for delivering CoQ10 into dermis site by evaluating its antiageing activity through analysis of collagen density and fibroblast counts. The drug release has not been performed yet and it becomes the lack of this study which need to be further determined.

Line 361-368: Protransf-CoQ10 Emulgel produce potential use for antiageing products, however, there are some lack informations about drug release profile as well as dermal penetrability to support the idea how the protransfersome and its incorporation into emulgel would become good model for developing skin antiageing cosmetics. Moreover, the ability of protransfersome and protransfersomal emulgel in maintaining drug stability and also physicochemical properties of skin dosage forms need to be evaluated for drug levels during study periods referring to ICH guideline. So, the product development could be comprehensively analyzed.

15. Answer:

Actually we also performed skin penetration study for 3 hours application; however, there was an accident that haematoxyllin-Eosin was added to the tissue section, so we could not observe Nile red-labelled Protransf-CoQ10 gel, as shown in the figures below.

But, the key point of anti-ageing efficacy was well observed by determining collagen density and fibroblast counts, thus enabling to conclude the study.

17. Answer:

In the DSC study, we would like to evaluate the effects of incorporation CoQ10 into protransfersome and it can be seen in Figure 4 that the CoQ10 encapsulation into protransfersome produced changes in the structure of crystallinity. In addition, the melting points of pure L- α -Phosphatidylcholine is 226 or 236°C. However, in this study, we used egg yolk L- α -Phosphatidylcholine with the purity of about 60%, therefore, there is no sharp peaks observed in this temperature. The use of wide range i.e. 30-300°C is intended

to observe whether there are some changes in higher melting points, as observed in our previous studies (Miatmoko *et al.* 2021).